Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
A phase 3 trial testing Givinostat in myeloproliferative neoplasms, now recruiting.
Overview
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera is a phase 3 interventional study registered as NCT06093672, led by Italfarmaco with PPD Development, LP, and recruiting when checked on 2026-09-11. Official title: Randomised, Open-label, Multicenter Phase 3 Study to Assess the Efficacy and Safety of GIVinostat Versus Hydroxyurea IN JAK2V617F-positive High-risk Polycythemia Vera Patients: the GIV-IN PV TRIAL. Planned enrolment is 220 participants (estimated). The study started in 2024-03-26 and primary completion is expected in 2026-07. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag ctgov-ingest.
- TrialStudy of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag ctgov-ingest.
- TreatmentBomedemstat
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag ctgov-ingest.
- TreatmentNavitoclax
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag ctgov-ingest.
- TreatmentKRT-232
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag ctgov-ingest.